Understanding the Market | BRONCUS-B rose over 9% during the session, planning to raise approximately HKD 327 million through a premium placement, with INT MEDICAL subscribing to the majority of the shares

BRONCUS-B rose over 9% during the session, and as of the time of writing, it is up 5.86%, priced at HKD 3.25, with a transaction volume of HKD 11.7892 million. In terms of news, BRONCUS announced that it plans to issue a total of 105 million subscription shares at a price of HKD 3.11 per share, which represents a premium of about 1.3% over the closing price of the previous trading day. The net proceeds are expected to be approximately HKD 327 million, intended for the continued expansion of its product portfolio through potential acquisitions in the medical device industry. The company has been seeking potential acquisition targets in the medical device sector and is currently in communication with various parties. Notably, in this placement, INT MEDICAL plans to invest approximately HKD 283 million to subscribe for about 91.0936 million shares of BRONCUS. The announcement stated that considering BRONCUS's rich product line in the non-vascular interventional field, the subscription could further expand the company's strategic layout in the non-vascular interventional area